This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Privacy Overview
Leap Therapeutics, Inc. (LPTX) is decreasing in the aftermarket – What is the news behind it?
Leap Therapeutics, Inc. (LPTX) saw a decrease of 8.21% after LPTX Announces the Proposed Public Offering of Common Stock and Pre-Funded Warrants. However, the last trading session closed at $3.41 with an increase of 23.1%.
Proposed Public Offering of Common Stock and Pre-Funded Warrants
LPTX announced on 1st September 2021 that Leap has started an underwritten public offering of its common stock. The company plans to issue and sell pre-funded warrants to buy shares of its common stock to specified investors. Moreover, Leap will sell all of the common stock and warrants in the offering. Leap wants to provide the underwriters a 30-day option to buy up to 15% more of the securities in the public offering.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The offering is subject to market, regulatory, and other circumstances, and no guarantee can be given as to whether or when it will be completed, or as to the actual size or terms of the offering. The offering’s book-running managers will be Piper Sandler & Co., Raymond James & Associates, Inc., and Mizuho Securities USA LLC. The offering’s lead manager will be Robert W. Baird & Co. Incorporated.
LPTX Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress
LPTX revised positive data from the first-line cohort of the DisTinGuish study on 16th September 2021. Patients with high levels of DKK1 expression, who have a bad prognosis, exhibited positive responses to therapy. The additional data presented shows evidence that DKK1 is not only a critical biomarker in predicting response to DKN-01 and tislelizumab therapy but that the combination can activate many responses regardless of the PD-L1 status of the patient.
Second Quarter 2021 Financial Results
LPTX announced second-quarter 2021 financial results on 13th September 2021.
Most Popular
Icon Energy Stock Surges On Dividend Announcement And Strategic Developments
FreightCar America (RAIL) Experiences Significant Market Upsurge
Cheche Group (CCG) Stock Rises As Earnings Report Looms
Strong Financial Report Drives Mobix Labs (MOBX) Share Price Up
Related Posts
Icon Energy Stock Surges On Dividend Announcement And Strategic Developments
FreightCar America (RAIL) Experiences Significant Market Upsurge
Cheche Group (CCG) Stock Rises As Earnings Report Looms
Strong Financial Report Drives Mobix Labs (MOBX) Share Price Up